From TB to HIV/AIDS to cancer, disease tracking has always had a political dimension, but it's the foundation of public health
Federal datasets began disappearing from public view on Jan. 31, 2025, in response to executive orders from President Donald Trump. Among those were the Centers for Disease Control and Prevention's Youth Risk Behavior Survey, which asks respondents about their gender identity and sexual orientation and tracks behaviors like smoking and drug use; CDC's HIV dataset; and CDC and Agency for Toxic Substances and Disease registry's Environmental Justice Index, which tracks pollution in communities, and Social Vulnerability Index, which identifies communities at high risk for disease and disability.
The collection of public health surveillance data has never been politically neutral. It has always reflected ideas about individual rights. With our colleagues James Colgrove and Daniel Wolfe, we have written about the history and ethics of surveillance. Despite controversy, it remains public health's foundational tool.
Surveillance typically involves tracking individuals with diseases by name for the purpose of direct action, including isolation, quarantine and treatment. It allows health officials to identify environmental threats and evaluate treatments. It allows governments to direct prevention and treatment resources where they are needed most, be that to a region or a group at highest risk. By the early 20th century, public health officials argued that without surveillance, they worked 'in the darkness of ignorance' and 'might as well hunt birds by shooting into every green bush.'
Three major controversies in the history of public health underscore what is at stake with the collection and maintenance of this information.
The collection of tuberculosis data provided the basic blueprint for public health surveillance.
Debates over tuberculosis reporting began in the late 19th century, when the bacterial infection was reframed not as a disease of the elite but of the urban poor. New York City was the first in the country to require that physicians report the names of TB patients in an effort to address the leading cause of death in both the city and the U.S.
The medical community bitterly resisted tuberculosis surveillance. A prominent New York City surgeon argued that surveillance represented a 'dictatorial … encroachment' of the health department that threatened to rob physicians of their patients.
But most people were not under the care of a private physician, and tuberculosis surveillance was a way to ensure that the largely immigrant poor living in the tenement districts got referrals to clinics, nourishment and, if necessary, isolation. Despite physicians' attempts to kill these efforts, there was no public outcry about tracking 'the great white plague' despite extensive, sensational coverage of the controversy in the popular press.
Debates around TB surveillance unfolded during a period in which both public health and medicine were highly paternalistic and authoritarian: Health department physicians or private physicians made medical decisions, not patients.
That changed with the AIDS epidemic, the first major infectious disease threat in more than a generation. AIDS arrived as American politics took a sharp conservative turn with the election of President Ronald Reagan. When in 1985 it became possible to test for HIV, the virus that causes AIDS, the prospect of named surveillance triggered deep fears about stigma and discrimination.
The prospect of reporting the names of those with HIV prompted one gay activist to declare, 'First comes the national registry, then come the boxcars, then come the camps for people with AIDS.' Gay rights advocates, who prioritized privacy, rejected HIV surveillance as a threat.
An alliance of gay rights leaders and civil liberties advocates was initially able to prevent health departments from undertaking named HIV surveillance. But by the end of the 1980s, there was growing pressure to return HIV/AIDS to 'the medical mainstream,' meaning that it could be managed therapeutically like other chronic conditions. As effective treatment became available in the 1990s, opposition faded, and all 50 states required named reporting.
If TB and HIV/AIDS reporting began as histories of resistance, the story was very different when it came to cancer reporting, which lagged far behind infectious disease surveillance.
In the wake of the environmental and women's movements, citizen activists, mothers of children with birth defects and women with breast cancer became alarmed about the threat of cancer linked to pesticides or industrial pollutants. Women with cancer asserted a 'right to be counted.' Although the National Cancer Act of 1971 directed the National Cancer Institute to 'collect, analyze, and disseminate all data useful in the prevention, diagnosis, and treatment of cancer,' by the 1980s, 10 states still had no registry.
Vermont's Bernie Sanders, then an independent member of the U.S. House of Representatives, called for a federally funded program to collect data on cancer in every state. Speaking in support of his bill in 1992, Sanders repeatedly invoked communities' right to know: 'We need to know the age of people who are coming down with cancer. We need to know where they live. We need to know the kind of work they do. We need their racial and ethnic backgrounds.'
President George H.W. Bush signed the Cancer Registries Amendment Act, which mandated cancer surveillance, into law in 1992. But it was not until 2000 that all states established cancer registries.
In the broader history of surveillance, two key lessons have emerged.
First, despite some pitched battles, communities have more often viewed surveillance as serving their interests.
Second, the system of public health surveillance in the U.S. remains an underfunded patchwork. The Pew Environmental Health Commission called birth defects surveillance 'woefully inadequate.' In 1972, the U.S. House Committee on Government Operations described occupational disease surveillance as '70 years behind infectious disease surveillance and counting.' In 2010, we ourselves observed that it was now 'a century behind and counting.'
The scope of the changes that the Trump administration has planned for federal data systems and datasets is unclear. Per a federal court order, key public health surveillance systems and datasets are back online. But the landing pages for both the Social Vulnerability Index and the Youth Risk Behavior Survey display a caveat based in politics rather than science that 'any information on this page promoting gender ideology is extremely inaccurate and disconnected from the immutable biological reality that there are two sexes, male and female.'
Systems can be compromised if datasets are scrubbed of key variables that enable public health action with populations at highest risk, are halted, or are removed from the public eye. Communities cannot act on what they cannot count.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Amy Lauren Fairchild, Syracuse University and Ronald Bayer, Columbia University Mailman School of Public Health
Read more:
COVID-19 is the latest epidemic to show biomedical breakthroughs aren't enough to eliminate a disease
Public health surveillance, from social media to sewage, spots disease outbreaks early to stop them fast
How to find climate data and science the Trump administration doesn't want you to see
Amy Lauren Fairchild has received funding from NIH and the RWJ Foundation. She currently receives funding from the Commonwealth Fund, the Mellon Foundation, and the National Science Foundation.
Ronald Bayer has received funding from the RWJ Foundation and NIH.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Opinion - Beyond MAHA: Defeating obesity requires a new strategy
Obesity is a major health problem facing our country. According to the CDC, more than 40 percent of the U.S. population is obese, defined as having a body-mass index above 30. As astounding at that number is, it is perhaps even more surprising that nearly 20 percent of children in the U.S. are obese. Obesity leads to significant health challenges, including diabetes, stroke, cardiovascular disease and liver disease. It is clear that as a nation we must face this crisis on multiple fronts. Diet and exercise certainly help, and it's critical to ensure that people of all socioeconomic backgrounds have access to healthy foods (free of preservatives, unnecessary dyes, high fructose corn syrups etc.) and are educated in making healthy lifestyle choices. The MAHA or 'Make America Healthy Again' movement has highlighted this as one of its key objectives, and if it is successful, we should see an impact on obesity — especially in children, where diet and exercise have a huge impact on weight-related health outcomes. Obesity in adults, however, is often more challenging. Many adults with obesity struggle to lose weight, despite considerable efforts to modify their lifestyle through diet and exercise. This is because our metabolism changes as we age, and many adults who are overweight develop metabolic dysfunction or 'metabolic syndrome,' which then further perpetuates weight gain and exacerbates the situation. It has become clear in recent years that many people struggling with obesity require medical intervention – not just lifestyle intervention – and that prescriptions can substantially improve weight loss. The explosion in use of GLP-1 agonists, such as Wegovy and Zepbound, over the last two years has underscored the need for medical intervention in obese and overweight patients. Currently, about 6 percent of the U.S. population, or 15 million people, are on GLP-1 weight loss treatments, and the numbers are only expected to increase. However, while most patients lose 10 percent to 25 percent of their body weight while on a GLP-1, they do not maintain GLP-1 treatment in the long-term, with approximately 80 percent of patients discontinuing treatment within 1 year. Gastrointestinal side effects, injectable administration, and high cost have prevented long-term use of GLP-1's for weight maintenance. And unfortunately, most patients gain back all the weight after stopping the medication. Healthcare professionals and the pharmaceutical industry now recognize that obesity — like most other medical conditions — requires an 'arsenal' of treatments, rather than a one-size-fits-all approach. Post-GLP-1 weight maintenance is now widely recognized as an emerging unmet need. And patients who are not candidates for or cannot tolerate GLP-1s require alternatives. Diet and lifestyle modifications are important alongside prescription medications in fighting obesity. If we are going to be successful in overcoming this major health crisis, we need to ensure that both the pharmaceutical industry and groups like MAHA work hand in hand. Both treatment and prevention are critical in order to regain control of our nation's health. Dr. Shoshana Shendelman, Ph.D. is a scientist and entrepreneur who has founded numerous biotech companies. She is a pioneer in the development of drugs and therapeutics for rare and underserved diseases. Currently she is Vice Chair of the Advisory Board of Columbia University Medical Center and Columbia University Vagelos College of Physicians and Surgeons. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.


Fox News
an hour ago
- Fox News
Obama WH physician says Biden doc should have performed cognitive test
Former President Barack Obama's White House physician said in a new interview that former President Joe Biden's doctor should have performed a cognitive test to evaluate his fitness to serve in office. Obama's doctor, Jeffrey Kuhlman, told The Washington Post that Biden White House physician Kevin O'Connor should have performed a cognitive test during Biden's last year as president, given his age. O'Connor, who Kuhlman first appointed as Biden's doctor in 2009 when he was vice president, declared in a 2024 report that the then-81-year-old president "continues to be fit for duty." The report did not mention any neurocognitive testing. "Sometimes those closest to the tree miss the forest," Kuhlman told the Post. "It shouldn't be just health, it should be fitness," Kuhlman said. "Fitness is: Do you have that robust mind, body, spirit that you can do this physically, mentally, emotionally demanding job?" Kuhlman, who departed the White House Medical Unit in 2013, described O'Connor as "a good doctor" who appeared to do his best to "give trusted medical advice." "I didn't see that he's purposely hiding stuff, but I don't know that," Kuhlman told the Post. "Maybe the investigation will show it." President Donald Trump on Wednesday ordered Attorney General Pam Bondi to investigate whether Biden's aides "abused the power of Presidential signatures through the use of an autopen to conceal Biden's cognitive decline and assert Article II authority." "This conspiracy marks one of the most dangerous and concerning scandals in American history," the order says. "The American public was purposefully shielded from discovering who wielded the executive power, all while Biden's signature was deployed across thousands of documents to effect radical policy shifts." "Let me be clear: I made the decisions during my presidency," Biden said in a statement Wednesday night. "I made the decisions about the pardons, executive orders, legislation, and proclamations. Any suggestion that I didn't is ridiculous and false." Trump's order appeared to nod to the findings of special counsel Robert Hur, who investigated Biden's handling of classified documents while he was vice president. In a report released in February 2024, Hur concluded Biden "willfully retained and disclosed" sensitive materials but should not stand trial, describing the president as a "sympathetic, well-meaning, elderly man with a poor memory." Hur cited instances when Biden could not recall key dates and events, including when he served as vice president and when his son, Beau, passed away. The report was released at a time when Biden was still planning a second term run. Last week, House Oversight Committee Chairman Rep. James Comer, R-Ky., issued a subpoena for O'Connor to appear for a deposition at the end of the month "as part of the investigation into the cover-up of President Joe Biden's cognitive decline and potentially unauthorized issuance of sweeping pardons and other executive actions." The committee re-posted the Post's interview with Kuhlman to X, writing, "Even Obama's doctor admits the truth. This is precisely why Chairman @RepJamesComer subpoenaed Dr. Kevin O'Connor, Biden's physician. This is a scandal of historical proportions, and we will investigate it thoroughly!" In a letter to O'Connor, Comer said the transcribed interview would focus on the physician's February 2024 assessment that Biden was "a healthy, active, robust 81-year-old male, who remains fit to successfully execute the duties of the Presidency." "Among other subjects, the Committee expressed its interest in whether your financial relationship with the Biden family affected your assessment of former President Biden's physical and mental fitness to fulfill his duties as President," Comer wrote. Questions about Biden's cognitive state stretch extend solely past Republicans. CNN's Jake Tapper and Axios' Alex Thompson recently published a book titled "Original Sin," which details concerns and debates inside the White House and Democratic Party over Biden's mental state and age. In the book, Tapper and Thompson wrote, "Five people were running the country, and Joe Biden was at best a senior member of the board." Naomi Biden, the former president's granddaughter, dismissed the book as "political fairy smut for the permanent, professional chattering class." Comer requested transcribed interviews with Biden's White House senior advisers Mike Donilon and Anita Dunn, former White House chief of staff Ron Klain, former deputy chief of staff Bruce Reed and Steve Ricchetti, a former counselor to the president. He also called for former senior White House aides Annie Tomasini, Anthony Bernal, Ashley Williams and Neera Tanden to appear before the committee and suggested subpoenas could be forthcoming if they did not schedule voluntary interviews.
Yahoo
2 hours ago
- Yahoo
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A new COVID variant known as NB.1.8.1 has made landfall in the United States. The variant, which was first detected in China this past January, currently accounts for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks ago. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. To date, only 20 NB.1.8.1 sequences have been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women Trump's FDA Has Axed COVID Boosters For Most People — And Medical Experts Are Deeply Worried New Trump Vaccine Policy Limits Access To COVID Shots